U of Minnesota, Celladon Researchers Collaborate on HT Assay for Heart Failure Rxs | GenomeWeb

NEW YORK (GenomeWeb News) – Researchers from the University of Minnesota and biotech firm Celladon have developed a high-throughput screening method that may help speed the development of drugs to treat heart failure, the university said this week.

Celladon, based in La Jolla, Calif., recently licensed exclusive rights to the technology from UM, and continues to work with researchers at the university to explore how the assay might be applied to other diseases, and to possibly conduct a large-scale screening campaign for drug candidates, officials said this week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.